Could a stroke drug help dementia patients?
NCT ID NCT03804229
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether butylphthalide soft capsules can improve thinking, memory, and daily living skills in people with mild to moderate vascular dementia. About 707 participants are randomly assigned to receive either the drug or a placebo for 52 weeks. The study aims to confirm earlier promising results from a Phase 2 trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Butylphthalide soft capsule
- What this could lead to
- If successful, this could provide a new treatment option to slow cognitive decline and improve daily function in people with vascular dementia.
- What could go wrong
- This is a Phase 3 trial, but results are not yet published. The drug may not show significant benefit over placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR DEMENTIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can tracking thousands of dementia cases reshape how we care for patients?
- Brain scans track Alzheimer's clues over decades
- Dementia agitation drug trial halted after just 5 patients
- Alzheimer's drug trial pulled before it even started
- Touchscreen device aims to give voice to dementia patients